Because of the progressive loss of nigro-striatal dopaminergic terminals in Parkinson's disease (PD), in vivo quantitative imaging of dopamine (DA) containing neurons in animal models of PD is of critical importance in the preclinical evaluation of highly awaited disease-modifying therapies. Among existing methods, the high sensitivity of positron emission tomography (PET) is attractive to achieve that goal. The aim of this study was to perform a quantitative comparison of brain images obtained in 6-hydroxydopamine (6-OHDA) lesioned rats using two dopaminergic PET radiotracers, namely
Parkinson's disease (PD) is a progressive neurodegenerative disorder that leads to severe motor and non-motor disabilities (Dickson et al. 2009 ). Cardinal motor symptoms of the disease are bradykinesia, rigidity and tremor. This triad results from the initial loss of pigmented dopamine-secreting neurons in the substantia nigra pars compacta. The firstchoice treatment for PD is still based on dopamine (DA) replacement using pro-drug Levodopa (L-DOPA). While symptoms of the disease may be alleviated through L-DOPA medication, it does not halt the underlying neuronal degeneration. Besides, the response to L-DOPA changes with disease's progression, with most of the patients developing dyskinesia and motor fluctuations ('wearing off phenomenon') within a few years of L-DOPA therapy (Rascol et al. 2000) .
During the past decades, promising strategies to address PD therapy have been developed (Isacson and Kordower 2008; Palfi et al. 2014) . However, these therapeutic approaches highlight the need for longitudinal measurements in animal models of PD to evaluate the efficacy of such treatments, and to explore the underlying mechanisms. Accordingly, biomarkers such as radiopharmaceuticals for positron emission tomography (PET) imaging are useful to differentiate PD from atypical Parkinsonism and to assess treatment response in clinical trials (Stoessl et al. 2014) .
L-3,4-dihydroxy-6-[ 
]FDOPA) has been developed as a PET radiotracer for DA synthesis, storage and turnover (Garnett et al. 1983) . Thus, [ 18 F] FDOPA was extensively used to assess in vivo the dopaminergic presynaptic lesions in PD patients, and more recently in animal models of PD (Pate et al. 1993; Kyono et al. 2011; Walker et al. 2013) . However, the [ 18 F]FDOPA PET presents several limitations related to its chemical structure which is very close to the natural analogue L-DOPA and consequently leads to suboptimal PET imaging characteristics. Indeed, [ 18 F]FDOPA undergoes all metabolic steps of L-DOPA, mainly decarboxylation by aromatic L-amino acid decarboxylase (AADC), storage into DA terminals by vesicular monoamine transporters, and catabolization by monoamine oxidase and catechol-O-methyltransferase (COMT) (Melega et al. 1991; Endres et al. 1997) . The action of the latter in the peripheral vascular compartment produces the metabolite 3-O-methyl-[ F]FD), which readily crosses the bloodbrain barrier, distributes uniformly and occupies a large volume of distribution in the brain, complicating interpretation of data (enhanced background noise and lower image contrast). In addition, to achieve accurate [ 18 F]FDOPA PET quantification, modelling approaches must therefore take into account a second input function for 3OM-[ 18 F]FD by means of serially collected blood samples (Doudet et al. 1991; Dhawan et al. 1996) . This methodology is highly restrictive in routine studies and reduces the non-invasive nature of PET examinations. Nonetheless, peripheral COMT inhibition has been effectively performed to reduce the 3OM-[ (Sawle et al. 1994; Holden et al. 1997) .
As an alternative, DOPA analogues that are not COMT substrates were developed (DeJesus and Mukherjee 1988 (Barrio et al. 1996; DeJesus et al. 1997) (Nahmias et al. 1995; Endres et al. 1997) . A major drawback limiting a widespread use of these [ 18 F]fluoro amino acids has long been the electrophilic labelling method. Since simpler nucleophilic methods allowing higher specific activity are available, they will become the gold standard production procedures.
Preclinical rodent models of PD are critical for the development of new drug candidates. The unilateral 6-hydroxydopamine (6-OHDA) rat model has been extensively used to test novel symptomatic agents as well as to provide a tool to assess disease-modifying strategies (Ungerstedt and Arbuthnott 1970; Duty and Jenner 2011; Fuzzati-Armentero et al. 2015) . This model exhibits a strong nigro-striatal tract degeneration, which translates into a robust behavioural phenotype, and a specific vulnerability to dyskinesia associated to L-Dopa treatment. However, the behavioural deficits, as measured under apomorphine challenge, are not likely to occur with a lesion of less than 80% (Schwarting and Huston 1996) .
This study aimed at comparing information provided by [
F]FMT PET and [
18 F]FDOPA PET, both produced at high specific activity, in unilaterally 6-OHDA-injected rats with partial and full lesion and sham-treated rats. Supported by a better signal-to-noise ratio and its high affinity for the AADC, we hypothesised that the [ 18 F]FMT will be revealed as a more sensitive radiotracer to target 6-OHDA-induced DA terminals injury. We applied several analysis techniques to see which one allows better highlighting of the differences between the two tracers. We started with qualitative assessment of PET images, and pursued with quantitative measures obtained by kinetic modelling. We aim to correlate those quantitative results with the DA lesion score based on the post-mortem measure of the striatal DA content, and to compare them with the rotational behaviour. Finally, we assessed the possibility of voxel-based analysis with both tracers in this rat model of PD. ]FMT with radiochemical yields of 36 AE 3% and 30 AE 5% (decay corrected), respectively. In both cases, at the end of synthesis the enantiomeric purity was ≥ 96%, the specific activity was more than 555 GBq/lmol and the radioactivity concentration more than 1.1 GBq/mL.
Materials and methods

Radiosynthesis
Animals and experimental design
All animal experiments were performed according to the Helsinki declaration and conducted in accordance with the European guidelines for care of laboratory animals (2010/63/EU). All procedures were reviewed and approved by the Institutional Animal Care and Use Ethics Committee of the University of Li ege, Belgium (LA1610005). Animals were housed in individually ventilated cages (2 per cages, room maintained at 22°C and at humidity of approximately 50%, 12-h day-night cycle). 26 male SpragueDawley rats (Janvier, France) were used for all experiments, their mean body weight AE SD at PET testing was 498 AE 58 g. Standard pellet food and tap water were provided ad libidum. Twenty-six rats were assigned by the experimenters to the following lesion condition: sham (n = 10, as control for the two lesion procedures), partial lesion (n = 8) and full lesion (n = 8). 6-OHDA was administered unilaterally and surgical procedure was performed as previously described (Michel et al. 2014) . Briefly, after imipramine administration (to protect noradrenergic neurons) and ketamine/ xylazine anaesthesia, 4 lg of 6-OHDA (2 lg/lL, total of 2 lL per rat), injected in the substantia nigra, and 10 lg of 6-OHDA (4 lg/ lL, total of 2.5 lL per rat), injected in the right ascending medial forebrain bundle, were delivered in the rat brain to induce, respectively, a partial and a full dopaminergic lesion (coordinates relative to the bregma and to the surface of the dura; partial lesion AP = À5.0, ML = À2.10, DV= À8.0; full lesion: AP = À3.5, ML = À1.5, DV = À8.7). Ten sham-treated rats were injected with vehicle only but otherwise treated identically. Minimum sample size (required to discriminate the radiotracer uptake between the lesioned and the contralateral striatum) was estimated at a power of 0.8 and an alpha level of 0.05 on the basis of large effects size and on data from previous published studies (Kyono et al. 2011; Walker et al. 2013 ) and preliminary results from this laboratory.
Behavioural testing: rotational activity in rotometers On day 21 after 6-OHDA or saline administration, all rats were challenged with a low subcutaneous dose of apomorphine (0.05 mg/ kg). Experimenters were blind of the surgical condition at the time of the testing. Eight chambers were placed on a level, clear glass bottom, held by a frame, and were subdivided into four individual test cages measuring 25 9 22 cm. Rats were fixed in a harness and linked to mechanical sensors connected directly to a computer. Each 360°clock-wise or counter clock-wise turn was automatically recorded for up to 45 min. The results were expressed as the percentage of contralateral turns out of the total number of turns.
Imaging data acquisition
Imaging data started 10 weeks after 6-OHDA or saline administration. Animals were placed in a prone position in a dedicated bed and anesthetized using 1-2% isoflurane in air at 0.6 l/min. Any bias from head movements was reduced using a stereotaxic holder (Minerve, France). Fiducial markers were used to optimize spatial co-registration between PET and magnetic resonance imaging (MRI) data. Respiration rate and rectal temperature were permanently measured using a physiological monitoring system (Minerve, France). Temperature was maintained at 37 AE 0.5°C, using an air warming system. All individuals underwent 2 PET scans on a Siemens FOCUS 120 microPET (Siemens, Knoxville, TN, USA) on 2 experimental sessions (mean interval = 11 AE 2 days). Thirty minutes before radiotracer injection, animals were all pretreated intraperitoneally with benserazide (10 mg/kg), a peripheral AADC inhibitor. For FDOPA scans, entacapone (peripheral inhibitor of COMT) was added (10 mg/kg) to the benserazide. PET data acquisition started with a 10-min Mean injected activities were 42.9 AE 3.7 MBq and 41.5 AE 5.1 MBq, respectively. Emission data were then recorded in list mode for a total of 60 min. Data were reframed as follows: 6 9 5 s, 6 9 10 s, 3 9 20 s, 5 9 30 s, 5 9 60 s, 8 9 150 s, 6 9 300 s. Images were reconstructed with all corrections, except for scatter events (Bahri et al. 2009 ), using Fourier rebinning and filtered backprojection with a ramp filter cutoff at the Nyquist frequency. A total of 95 transaxial slices were obtained in 256 9 256 matrix. The slice thickness was 0.796 mm, and the inslice pixel size was 0.433 mm.
Immediately after PET acquisition, the anesthetized rats were transferred (without having been awaked or moved) into a 9.4 Tesla MRI DirectDrive VNMRS horizontal bore system with a shielded gradient system (Agilent Technologies, Palo Alto, CA, USA) and a 72 mm inner diameter volumetric coil (Rapid Biomedical GmbH, W€ urzurg, Germany). Anatomical T2-weighted brain images were acquired with a fast spin echo multislice sequence using the following parameters: TR/TE eff = 2000/40 ms, matrix = 256 9 256, FOV = 45 9 45 mm, 30 contiguous slices (thickness = 0.80 mm, in-plane voxel size: 0.176 9 0.176 mm).
Imaging data processing PMOD software version 3.6 (PMOD Technologies Ltd., Zurich, Switzerland) was used to process the imaging data and to extract time activity curves (TACs) in volume of interests (VOIs) positioned over the left and right striatum and cerebellum of PET images. These VOIs were obtained using PMOD rat brain atlas. The structural MRI images were co-registered to the corresponding PET images by the aid of the fiducial markers. The co-registered MRI images were then spatially normalized onto the PMOD structural MRI image template. The inverse spatial normalization parameter estimates were applied to the PMOD rat brain atlas in order to bring it into the native dynamic PET space. Individual TACs were normalized by the injected dose and the animal weight, and then expressed in standardized uptake value (SUV).
For each individual, we created 2 sets of quantitative data. (i) First, we used the Patlak graphical model to compute the tissuederived uptake rate constant (K c ) in the left and right striatum VOIs, using the cerebellum as reference tissue (Supporting Information). The resulting K c data were thereafter expressed in terms of decrease in relation to the contralateral striatum (% of ispilateral K c decrease). (ii) Then, with the aim of performing voxel-based analyses of PET data, the Patlak model was applied to create parametric images representing [ Post-mortem DA quantitation Twelve weeks after the lesion, all rats were killed and each brain was rapidly removed. Striata from the lesioned and unlesioned hemispheres, were carefully dissected over ice and stored at À80°C until analysis. To measure the levels of DA, striatal tissue samples were homogenized in 1/20 (v/v) EDTA 0.3 mM/HClO4 0.05N and centrifuged at 21 000 g (15 000 rpm) at 4°C for 15 min. 5 lL of the supernatant were injected in an HPLC system (WATERS ALLI-ANCE 2695) coupled with an ElectroChemical Detector (ECD Antec Decade). The ECD was equipped with a working glassy carbon cell VT-03 2 mm, using as sensitivity range for 3,4-dihydroxyphenylacetic acid & DA 50 and 10 nA for homovanillic acid. The resulting DA data were then expressed in terms of depletion in relation to the contralateral striatum (% of ispilateral DA depletion), and referred as DA lesion score.
Statistical analysis
All results were expressed as the mean AE confidence interval of 95%. Statistical analyses were carried out using Statistica13 (Statsoft France) and GraphPad Prism (version 6, GraphPad software, Inc., San Diego, CA, USA). All the measures (% of contralateral turns, % of ispilateral [ 
Results
Behavioural data
For the rotational activity in rotometers, results are shown in Fig. 1a . The sham and partial lesion groups showed a % of contralateral rotations of 49.0 AE 11.1% and 35.5 AE 12.3% respectively. The full lesion group displayed a % of contralateral rotations of 98.1 AE 1.0%. The planned comparisons revealed significant differences in the contrasts sham versus full lesion: t(23) = 6.61, p < 0.001, ES = 3.13; and partial lesion versus full lesion: t(23) = 7.98, p < 0.001, ES = 3.99; whereas no significant difference was found for the contrast sham versus partial lesion: t(23) = 1.81, p = 0.084, ES = 0.86.
Post-mortem DA quantitation
The post-mortem ipsilateral DA depletions computed for all groups are presented in Fig. 1b . Those DA lesion scores (expressed as % of ipsilateral DA depletion) were 19.2 AE 4.6, 72.4 AE 5.1 and 99.0 AE 5.1 for the sham, the partial lesion and the full lesion groups respectively. All a priori contrasts highlighted the significant differences in the DA lesion scores between the three groups; contrast sham versus partial lesion: t(23) = 15.93, p < 0.001, ES = 7.56, contrast sham versus full lesion: t(23) = 23.88, p < 0.001, ES = 11.33, and contrast partial lesion versus full lesion: t (23) = 7.54, p < 0.001, ES = 3.77. The post-mortem concentrations of 3,4-dihydroxyphenylacetic acid and homovanillic acid are not reported here, because we were not able to detect any of them in striatum ipsilateral to the lesion in the 6-OHDA full lesion population rats. In those (Fig. 2a and c) (Fig. 2a and c) . The mean TACs from cerebellum and striata are represented in Fig. 2b and d . These curves confirmed, for both tracers, decreased accumulation in the ipsilateral striatum of both 6-OHDA injected groups. Fig. 2d ). Those inefficient inhibitions were likely as a result of an inappropriate intraperitoneal injection. In 1 out of 8 [ 18 F]FDOPA scans in the sham group, the intravenous injection of the radiotracer obviously failed. The TACs displayed a progressive accumulation reaching a maximum value around 1.2 at 60 min rather than the rapid accumulation with a maximum of 1.5 at 30 min after the injection observed in a normal TAC (see Fig. 2d ). These three outliers were not suitable for quantitative analysis and thus, were excluded from further analyses. Correlations between the ipsilateral K c decrease in both tracers and the DA lesion score were computed ( Fig. 5a and b) and revealed a higher spearman's rho coefficient for the [ F]FDOPA data, showed a significant decrease in mean K c for both 6-OHDA groups (partial and full lesion) in voxels lying in the striatum ipsilateral to the lesion (Fig. 6 , p < 0.001 uncorrected for both tracers). Throughout the rest of the brain, no significant decrease in K c was seen. The corresponding voxels and peak coordinates are shown in Table 2 . 
Quantitative PET data analysis
Discussion
The goal of this study was to compare the respective capacities of nca [
F]FMT and nca [
18 F]FDOPA, both at high specific activity, to assess and quantify DA terminals loss in a toxic rat model of PD. To that end, we scanned three groups of rats: unilaterally 6-OHDA-lesioned rats with partial and full lesion and their corresponding age-matched controls (sham), using both tracers and compared them over a wide range of analyses. Figure 1 shows the dramatic increase in the score of contralateral apomorphine-induced rotations in the full lesion group, while we were not able to detect any difference between the sham and the partial lesion group. This is consistent with previous studies reporting that the apomorphine-induced rotation test, although offering the most consistent and accurate assessment of near complete nigrostriatal DA depletion, would detect only DA denervation of more than 90% (Hudson et al. 1993; Schwarting and Huston 1996) . There is abundant literature that reports the reliability of striatal DA content as biochemical marker of striatal lesions (Pate et al. 1993; Snow et al. 1993 ). Our results confirm previous studies showing that apomorphine-induced rotational behaviour is a reliable predictor of extensive striatal lesions by 6-OHDA supporting its wide use as a behavioural index to evaluate the extent of the striatal denervation as support for pharmacological testing (Hudson et al. 1993; Deumens et al. 2002) .
Regarding the images shown in Fig. 2a and c, it is clear that both tracers are able to discriminate the striatum ipsilateral to the lesion from the contralateral one, as it has already been described in primate model of PD (Doudet et al. 1999) and PD patients (Gallagher et al. 2012) . Unlike the work of DeJesus et al. (1997) in monkeys, we were not able to visualize small nonstriatal dopaminergic areas such as the substantia nigra.
Tracer uptake was estimated using the Patlak reference model, which is based on graphical linearization analysis of dynamic PET data (Patlak and Blasberg 1985) . The tissuederived uptake rate constant K c values were in accordance with existing literature for [
18 F]FDOPA (Kyono et al. 2011) . As far as we know, this is the first study revealing quantification of [
18 F]FMT PET in rats, and the K c values presented here were consistent with those previously found in a primate model of PD (Doudet et al. 1999) . We found here that the K c of both tracers are tightly correlated (Fig. 3) as it was previously mentioned in the PD primates investigation (Doudet et al. 1999) . However, as reported in the Interestingly, sham-treated rats already display a DA lesion score of 19.2 AE 4.6% (Fig. 1b) . This is likely due to the surgery and in situ vehicle injection. However, neither [ (Fig. 4) Brain PET imaging studies are crucial for the screening of disease modifying therapies as well as for the clinical evaluations of PD's patients. In this context, reliable PET scan outcomes are useful translational tools allowing in vivo longitudinal follow-up. Although DA turnover assessment using [
18 F]FDOPA remains the most sensitive measure of early DA impairments, it requires a 3 h scan with full quantification and blood analysis (Doudet et al. 1999; Walker et al. 2013) . This complex and time-consuming methodology may not be compatible with intensive (Doudet et al. 1999; Kanazawa et al. 2016) . This probably relates to the lower background noise of the [ 18 F]FMT and to its 10-fold higher affinity towards the AADC enzyme (DeJesus and Mukherjee 1988) . Besides that, it has been suggested that residual AADC activity may be a major determinant of functional status in PD's patients (Gallagher et al. 2012 (Gallagher et al. 2012) . Our study suggests that [ 18 F] FMT could be more sensitive to detect DA lesion induced by 6-OHDA injection with microPET, and as a consequence seems a tracer of choice to investigate DA presynaptic integrity while focusing on AADC activity. Additional studies with longitudinal follow-up on progressive PD models, such as transgenic models, should provide robust data on the specificity of both radiotracers, and allow the validation of a new tool to assess in vivo the efficacy of novel disease-modifying strategies.
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